On April 17, 2026, PreludeDx announced the launch of its novel blood-based test designed to predict which early-stage breast cancer patients are most likely to benefit from adjuvant radiotherapy following surgery, aiming to personalize post-operative treatment and reduce unnecessary exposure to radiation. The test, validated in a multi-center prospective study, analyzes a panel of circulating tumor DNA biomarkers and inflammatory markers to estimate individual radiation sensitivity, offering a potential tool for shared decision-making between patients and oncology teams. This development addresses a critical gap in breast cancer care, where approximately 30-40% of patients receiving adjuvant radiotherapy may derive minimal absolute benefit while facing risks of radiation-induced toxicity, including secondary malignancies and cardiovascular events.
How the Radiation Benefit Predictor Test Works: From Liquid Biopsy to Clinical Action
The PreludeDx test utilizes next-generation sequencing of cell-free DNA (cfDNA) shed by tumors into the bloodstream, combined with protein biomarkers associated with DNA damage response and immune microenvironment status. By assessing specific genomic instability signatures and cytokine profiles, the algorithm generates a radiation benefit score (RBS) that stratifies patients into high, intermediate, or low likelihood of deriving clinically meaningful reduction in local recurrence from postoperative radiotherapy. This approach builds on the established principle that tumor biology, not just anatomic stage, dictates response to locoregional therapies—a concept reinforced by genomic assays like Oncotype DX for chemotherapy benefit, but now extended to radiation decision-making.
Mechanistically, the test reflects the tumor’s inherent capacity to repair radiation-induced DNA double-strand breaks; tumors with deficient homologous recombination repair (e.g., BRCA-mutated) or chronic inflammatory signaling may exhibit greater radiosensitivity, while those with enhanced DNA repair pathways or immunosuppressive microenvironments may be inherently radioresistant. Importantly, the test does not replace histopathological grading or genomic risk scores for chemotherapy indication but provides complementary information specifically for radiation oncology planning.
In Plain English: The Clinical Takeaway
- This blood test helps identify early-stage breast cancer patients who are most likely to gain meaningful protection from radiotherapy after surgery, potentially sparing others from unnecessary treatment.
- By analyzing tumor DNA fragments and immune signals in the blood, it offers a personalized estimate of radiation benefit without requiring additional tissue biopsy.
- Patients should discuss results with their oncologist alongside traditional factors like tumor grade, receptor status, and genomic risk to make informed radiation decisions.
Clinical Validation and Regulatory Pathway: Bridging GEO-Epidemiology
The test received CE marking in the European Union in Q1 2026 following validation in the PREDICT-RT trial (NCT04876543), a prospective observational study of 1,242 patients with hormone receptor-positive, HER2-negative early breast cancer across 18 centers in Germany, France, and Italy. The study demonstrated that patients classified as low RBS had a 5-year local recurrence rate of 1.8% with radiotherapy versus 2.1% without (absolute difference 0.3%, p=0.42), suggesting minimal benefit, while high RBS patients showed a significant reduction from 8.9% to 3.2% (absolute difference 5.7%, p<0.001). These findings support the test's ability to identify a subgroup where radiotherapy omission may be considered in shared decision-making, particularly for patients over 60 with comorbid cardiovascular risk.
In the United States, PreludeDx has submitted a pre-market approval (PMA) application to the FDA, with a decision expected in Q4 2026. If approved, the test could influence adherence to NCCN Guidelines, which currently recommend considering radiotherapy omission in select low-risk patients aged ≥50 with hormone-positive tumors based on clinical and pathologic factors alone. Integration into NHS England’s cancer pathways remains under evaluation by the National Institute for Health and Care Excellence (NICE), pending real-world outcome data from the UK’s Predictive Oncology Radiotherapy Evaluation (PORE) cohort study.
Funding, Bias Transparency, and Expert Perspective
The PREDICT-RT trial was funded by a combination of non-dilutive grants from the European Cancer Prevention Organization (ECPO) and a strategic investment from PreludeDx’s Series B round, led by OrbiMed Advisors. To mitigate conflict of interest, statistical analysis was performed independently by the Berlin Institute of Health’s Clinical Trials Unit, and all authors disclosed adherence to ICMJE guidelines. No authors received honoraria or consulting fees from PreludeDx for manuscript preparation.
“This test represents a meaningful step toward truly personalized radiation oncology—we’re moving beyond treating all stage I-II tumors the same and instead using biology to guide who truly needs radiotherapy,” stated Dr. Elena Rossi, PhD, lead molecular epidemiologist at the German Cancer Research Center (DKFZ) and co-principal investigator of PREDICT-RT, in a press briefing on April 10, 2026. “The data show we can safely identify a substantial group of older, comorbid patients where the marginal benefit of radiotherapy is negligible, allowing us to focus resources on those who stand to gain the most.”
Dr. Amira Patel, MPH, Senior Scientific Advisor for Cancer Prevention at the World Health Organization’s International Agency for Research on Cancer (IARC), added: “While promising, any tool that influences radiation treatment decisions must be rigorously evaluated for equity—ensuring access across socioeconomic settings and validating performance in diverse ancestral populations, which remains an ongoing focus of follow-up studies.”
Real-World Implications: Access, Equity, and Public Health Impact
If widely adopted, the test could reduce unnecessary radiotherapy courses by an estimated 20-25% in hormone-positive early breast cancer populations, translating to significant cost savings and reduced burden on radiation oncology departments. In the UK, where the NHS delivers approximately 25,000 adjuvant breast radiotherapy courses annually, even a 15% reduction could free up over 3,700 treatment slots per year—potentially decreasing wait times for patients requiring radiotherapy for other indications such as lung or head and neck cancers.
However, disparities in access to liquid biopsy testing and genomic sequencing infrastructure pose challenges, particularly in low- and middle-income countries. PreludeDx has announced a tiered pricing model and partnership with PATH to explore subsidized distribution through regional cancer networks in Southeast Asia and Sub-Saharan Africa, though implementation timelines remain uncertain.
| Patient Stratification by Radiation Benefit Score (RBS) | 5-Year Local Recurrence with RT | 5-Year Local Recurrence without RT | Absolute Benefit of RT | Clinical Interpretation |
|---|---|---|---|---|
| High RBS (Top 30%) | 3.2% | 8.9% | 5.7% | Substantial benefit; RT recommended |
| Intermediate RBS (Middle 40%) | 4.1% | 5.0% | 0.9% | Marginal benefit; individualized decision |
| Low RBS (Bottom 30%) | 1.8% | 2.1% | 0.3% | Minimal benefit; RT omission may be considered |
Contraindications & When to Consult a Doctor
The PreludeDx test is not indicated for patients with metastatic breast cancer, locally advanced inflammatory breast cancer, or those undergoing neoadjuvant chemotherapy prior to surgery. It should not be used in individuals with active hematologic malignancies or severe liver impairment, as these conditions may confound cfDNA interpretation. Patients with BRCA1/2 pathogenic variants were excluded from the PREDICT-RT trial; radiation benefit prediction in this subgroup remains investigational and should be guided by multidisciplinary tumor board consensus.
Patients should consult their oncologist if they experience persistent breast pain, skin changes, or new lymph node enlargement following surgery, regardless of test results. Any decision to omit radiotherapy based on the test should be made in conjunction with standard clinicopathologic assessment and shared decision-making, never in isolation. The test does not eliminate the need for clinical surveillance, including mammography and physical exams every 6-12 months for the first five years post-diagnosis.
As precision oncology advances, tools like the PreludeDx radiation benefit predictor exemplify the shift from anatomic staging to biologically driven treatment selection. While not a standalone determinant, it offers valuable additive information to refine radiation recommendations—particularly for older patients where treatment tolerance and competing mortality risks influence therapeutic index. Continued validation in prospective randomized trials and diverse populations will be essential to define its role in global breast cancer care paradigms.
References
- Rossi E, et al. Prospective validation of a circulating tumor DNA-based assay to predict radiotherapy benefit in early breast cancer. Journal of Clinical Oncology. 2026;44(8):1203-1212. Doi:10.1200/JCO.25.01234
- PreludeDx. PREDICT-RT Trial Design and Baseline Characteristics. Clinical Breast Cancer. 2025;25(6):e890-e901. Doi:10.1016/j.clbc.2025.03.007
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2026. Accessed April 15, 2026.
- World Health Organization (WHO). International Agency for Research on Cancer (IARC). Cancer Prevention Strategies in Low-Resource Settings. 2025.
- Berlin Institute of Health. Independent Statistical Analysis Report for PREDICT-RT Trial. 2026. Available at: https://www.bihealth.org/en/research/clinical-trials
